Clinical Trial Update: Surveillance Study of NovoRapid® for New Drug Re-examination

View source ↗

Summary

Surveillance study of NovoRapid for new drug re-examination has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoRapid (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED